Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.
The field of Alzheimer's disease (AD) research eagerly awaits the results of a large number of Phase III clinical trials that are underway to investigate the effectiveness of anti-amyloid-β (Aβ) immunotherapy for AD. In this case report, we review the pertinent clinical history, examine the neuropathology, and characterize the Aβ profile of an AD patient who received bapineuzumab immunotherapy. The patient received four bapineuzumab infusions over a 39 week period. During the course of this treatment, there was no remarkable change in cognitive impairment as determined by MMSE scores. Forty-eight days after the fourth bapineuzumab infusion was given, MRI revealed that the patient had developed lacunar infarcts and possible vasogenic edema, probably related to immunotherapy, but a subsequent MRI scan 38 days later demonstrated resolution of vasogenic edema. The patient expired due to acute congestive heart failure complicated by progressive AD and cerebrovascular accident 378 days after the first bapineuzumab infusion and 107 days after the end of therapy. Neuropathological and biochemical analysis did not produce evidence of lasting plaque regression or clearance of Aβ due to immunotherapy. The Aβ species profile of this case was compared with non-immunized AD cases and non-demented controls and found to be similar to non-immunized AD cases. SELDI-TOF mass spectrometric analysis revealed the presence of full-length Aβ₁₋₄₂ and truncated Aβ peptides demonstrating species with and without bapineuzumab specific epitopes. These results suggest that, in this particular case, bapineuzumab immunotherapy neither resulted in detectable clearance of amyloid plaques nor prevented further cognitive impairment.
Longtine Center for Neurodegenerative Biochemistry, Banner Sun Health Research Institute, Sun City, AZ 85351, USA. alex.roher@bannerhealth.com
Alex E
AE
Roher
Chera L
CL
Maarouf
Ian D
ID
Daugs
Tyler A
TA
Kokjohn
Jesse M
JM
Hunter
Marwan N
MN
Sabbagh
Thomas G
TG
Beach
D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D016229:Amyloid beta-Peptides / Q000378:metabolism; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001921:Brain / Q000378:metabolism / Q000473:pathology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D010446:Peptide Fragments / Q000378:metabolism; D058225:Plaque, Amyloid / Q000378:metabolism*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
C545487:APP protein, human; D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D010446:Peptide Fragments; D014409:Tumor Necrosis Factor-alpha; C078592:amyloid beta-protein (1-40); C545458:bapineuzumab
Am J Pathol. 2006 Sep;169(3):1048-63
16936277
Clin Chem. 2005 Sep;51(9):1650-60
16020497
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1550-5
9037091
Biochemistry. 2005 Aug 16;44(32):10810-21
16086583
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10256-61
20479234
Biochem Biophys Res Commun. 1997 Aug 8;237(1):188-91
9266855
Biochemistry. 2002 Jan 22;41(3):922-8
11790115
J Biol Chem. 2010 Jan 29;285(5):3417-27
19923222
Am J Pathol. 1997 May;150(5):1531-6
9137079
Biochem Biophys Res Commun. 1995 Jun 26;211(3):1015-22
7598687
Mol Neurodegener. 2010 Oct 07;5:39
20929585
Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10836-40
8248178
Neurology. 2005 Jan 11;64(1):129-31
15642916
J Biol Chem. 1998 Nov 6;273(45):29719-26
9792685
FEBS Lett. 1997 Jun 16;409(3):411-6
9224700
J Biol Chem. 2004 Feb 13;279(7):5829-36
14645225
J Biol Chem. 1993 Feb 15;268(5):3072-83
8428986
Am J Pathol. 2000 Dec;157(6):2093-9
11106581
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6538-43
20308552
Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S91-4
9330994
Acta Neuropathol. 1991;82(4):239-59
1759558
J Neurosci. 2008 Jul 2;28(27):6787-93
18596154
J Biol Chem. 1994 Apr 15;269(15):10987-90
8157623
Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S1-2
9330978
Mol Neurodegener. 2008 Nov 20;3:20
19021905
Neurodegener Dis. 2008;5(2):65-71
18182780
Dement Geriatr Cogn Disord. 2008;25(3):278-86
18303264
J Neurosci. 1996 Oct 1;16(19):6021-37
8815885
Biochemistry. 2005 Oct 25;44(42):13807-19
16229470
Neurology. 1993 Feb;43(2):250-60
8094895
Acta Neuropathol. 2010 Sep;120(3):369-84
20632020
Neurology. 2009 Dec 15;73(24):2061-70
19923550
Brain. 2002 Sep;125(Pt 9):2036-43
12183349
Neurology. 2005 Dec 27;65(12):1863-72
16237129
Ann N Y Acad Sci. 2000 Apr;903:118-22
10818496
J Neuropathol Exp Neurol. 2006 Nov;65(11):1040-8
17086100
Mol Med. 1998 Jul;4(7):480-9
9713826
Cell Tissue Bank. 2008 Sep;9(3):229-45
18347928
J Neurochem. 2003 Jun;85(6):1581-91
12787077
Lancet Neurol. 2010 Apr;9(4):363-72
20189881
J Neurosci. 2001 Jan 15;21(2):372-81
11160418
Alzheimers Res Ther. 2010 May 07;2(2):11
20497615
Am J Pathol. 1996 Jun;148(6):2083-95
8669492
Brain Pathol. 2004 Jan;14(1):11-20
14997933